Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

431739

registered interest
date	23/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Records: Data Protection
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he had with EMIS Health on data protection.
tabling member constituency	Hyndburn
tabling member printed	Graham Jones
uin	17384
answer	answer is ministerial correction date of answer 26/11/2015 answer text <p>No discussions between My Rt. hon. Friend the Secretary of State and EMIS about data protection have taken place.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/11/2015 16:26:33 answering member 4020 label Biography information for George Freeman
tabling member	3999 label Biography information for Graham P Jones

431742

registered interest
date	23/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Per Capita Costs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much NHS England spent per head on mental health in each year since 2008.
tabling member constituency	Central Suffolk and North Ipswich
tabling member printed	Dr Poulter
uin	17404
answer	answer is ministerial correction date of answer 26/11/2015 answer text <p>NHS England was formed in April 2013.</p><br /><p>The table below shows actual expenditure by clinical commissioning groups (CCGs) on mental health in 2013/14 and 2014/15 and forecast spend in 2015/16. This does not include spending on mental health services directly commissioned by NHS England.</p><p>Total actual expenditure by on mental health by CCGs across all providers for 2013/14 and 2014/15 and the total forecast expenditure for 2015/16</p><br /><table><tbody><tr><td><p>2013/14 actual spend (£ <ins class="ministerial">billion </ins><del class="ministerial">million</del>)</p></td><td><p>2014/15 actual spend (£ <ins class="ministerial">billion</ins><del class="ministerial">million</del>)</p></td><td><p>2015/16 forecast spend (£ <ins class="ministerial">billion </ins><del class="ministerial">million</del>)</p></td></tr><tr><td><p>9.6</p></td><td><p>10.1</p></td><td><p>10.6</p></td></tr></tbody></table><br /><p><em>Source:</em> NHS England</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/11/2015 16:25:03 question first ministerially corrected 02/12/2015 14:16:07 answering member 4020 label Biography information for George Freeman previous answer version 32352 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	3932 label Biography information for Dr Dan Poulter

429394

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Marketing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for which drugs he is the marketing authorisation holder; and under what circumstances he became the marketing authorisation holder for each such drug.
tabling member constituency	Torfaen
tabling member printed	Nick Thomas-Symonds
uin	17006
answer	answer is ministerial correction date of answer 24/11/2015 answer text <br /><p>The Secretary of State currently holds a market authorisation for one drug, Healthy Start Children’s Vitamins Drops.</p><br /><p>This product was originally granted a licence in 1972 as licence of right. The reasons for this likely stem from the need to ensure supply of this product when a commercial supply of a similar product could not be procured.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2015 17:35:44 answering member 4020 label Biography information for George Freeman
tabling member	4479 label Biography information for Nick Thomas-Symonds

429395

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Off-patent Drugs Bill
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with the Association of the British Pharmaceutical Industry on the Off-patent Drugs Bill.
tabling member constituency	Neath
tabling member printed	Christina Rees
uin	17000
answer	answer is ministerial correction date of answer 25/11/2015 answer text <br /><p>The Association of the British Pharmaceutical Industry attended and contributed to the Department’s Roundtable Event of February 2015 <em>‘Translating evidence in to clinical practice’ </em>which gathered key stakeholders including Breast Cancer Now and other charities, the Medicines and Healthcare products Regulatory Agency, the British Generic Manufacturers Association, the Royal College of Paediatrics and Child Health and many other NHS organisations.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/11/2015 15:08:30 answering member 4020 label Biography information for George Freeman
tabling member	4525 label Biography information for Christina Rees

429397

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antibiotics: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what financial support his Department has provided for research into antibiotic resistance in each of the last five years; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	17038
answer	answer is ministerial correction date of answer 24/11/2015 answer text <br /><p>The information requested is not available. The Department funds research through the National Institute for Health Research (NIHR) and the Department’s Policy Research Programme (PRP). Spend on research funded directly by the NIHR is categorised by Health Research Classification System (HRCS) health categories. There are no HRCS health sub-categories, and no category or sub-category for antibiotic resistance.</p><br /><p>On 18 November 2015 the NIHR announced funding for 16 studies relating to antimicrobial resistance with an investment of over £15.8 million to date, with funding of further projects expected during 2015.</p><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2015 17:36:53 answering member 4020 label Biography information for George Freeman
tabling member	308 label Biography information for Mr Jim Cunningham

429398

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NICE on conducting health technology appraisals for off-patent drugs that have been proven to be effective in new indications.
tabling member constituency	Torfaen
tabling member printed	Nick Thomas-Symonds
uin	17007
answer	answer is ministerial correction date of answer 24/11/2015 answer text <p>My Rt. hon. Friend the Secretary of State has had no discussions with the National Institute for Health and Care Excellence (NICE) on the subject of technology appraisals for off-patent drugs in new indications. NICE does not routinely appraise drugs outside their licensed indications.</p><br /><p>NICE does, however, issue evidence summaries which summarise the published evidence for selected unlicensed or off-label medicines that are considered to be of significance to the NHS, where there are no clinically appropriate licensed alternatives. They support decision-making on the use of an unlicensed or off-label medicine for an individual patient, where there are good clinical reasons for its use, usually when there is no licensed medicine for the condition requiring treatment, or the licensed medicine is not appropriate for that individual. Examples of evidence summaries can be found at:</p><br /><p><a href="http://www.nice.org.uk/advice?type=esuom" target="_blank">http://www.nice.org.uk/advice?type=esuom</a></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2015 17:34:24 answering member 4020 label Biography information for George Freeman
tabling member	4479 label Biography information for Nick Thomas-Symonds

429400

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what guidance his Department has provided for clinical commissioning groups on the commissioning of off-patent drugs for use in new indications.
tabling member constituency	Torfaen
tabling member printed	Nick Thomas-Symonds
uin	17022
answer	answer is ministerial correction date of answer 24/11/2015 answer text <p>NHS England supports the national commissioning system in England, including the provision of guidance to the service, where appropriate.</p><br /><p>The National Institute for Health and Care Excellence (NICE) does not routinely appraise drugs outside their licensed indications. Where drugs are not appraised by NICE, it is the responsibility of clinical commissioning groups (CCGs) to decide how drugs should be funded locally, in line with any guidance from NHS England. The Department has produced no guidance and had no discussions with CCGs on off-label drug use.</p><br /><p>Many thousands of patients benefit from the use of off-patent drugs, off-label, every day in the National Health Service. NICE publishes Evidence Summaries on unlicensed and off-label medicines. These provide a summary of the published evidence for selected unlicensed or off-label medicines that are considered to be of significance to the NHS, usually when there is no licensed medicine for the condition requiring treatment or no licensed medicines are appropriate for a significant proportion of people requiring treatment.</p><br /> <br /> <br /> <br /> <br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 17023 question first answered 24/11/2015 17:15:52 answering member 4020 label Biography information for George Freeman
tabling member	4479 label Biography information for Nick Thomas-Symonds

429401

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with clinical commissioning groups on commissioning of off-patent drugs for use in new indications.
tabling member constituency	Torfaen
tabling member printed	Nick Thomas-Symonds
uin	17023
answer	answer is ministerial correction date of answer 24/11/2015 answer text <p>NHS England supports the national commissioning system in England, including the provision of guidance to the service, where appropriate.</p><br /><p>The National Institute for Health and Care Excellence (NICE) does not routinely appraise drugs outside their licensed indications. Where drugs are not appraised by NICE, it is the responsibility of clinical commissioning groups (CCGs) to decide how drugs should be funded locally, in line with any guidance from NHS England. The Department has produced no guidance and had no discussions with CCGs on off-label drug use.</p><br /><p>Many thousands of patients benefit from the use of off-patent drugs, off-label, every day in the National Health Service. NICE publishes Evidence Summaries on unlicensed and off-label medicines. These provide a summary of the published evidence for selected unlicensed or off-label medicines that are considered to be of significance to the NHS, usually when there is no licensed medicine for the condition requiring treatment or no licensed medicines are appropriate for a significant proportion of people requiring treatment.</p><br /> <br /> <br /> <br /> <br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 17022 question first answered 24/11/2015 17:15:52 answering member 4020 label Biography information for George Freeman
tabling member	4479 label Biography information for Nick Thomas-Symonds

429404

registered interest
date	19/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Records: Internet
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when all NHS patients will be able to access their medical records online; and when the NHS will implement a secure unified email system.
tabling member constituency	Twickenham
tabling member printed	Dr Tania Mathias
uin	16976
answer	answer is ministerial correction date of answer 24/11/2015 answer text <p>From April 2015 patients have had online access to summary information in their general practitioner (GP) records relating to allergies, adverse reactions and medications. By the end of March 2016, general practices are required to offer online access to coded information, such as problem diagnoses, procedures and test results in GP clinical records.</p><br /><p>The National Health Service has used a secure email service, NHSmail, for the last 12 years. This service is available for use by organisations commissioned to deliver NHS health and care or related activities.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2015 17:11:53 answering member 4020 label Biography information for George Freeman
tabling member	4404 label Biography information for Dr Tania Mathias

429071

registered interest
date	18/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will discuss with NICE and the Roche group of companies steps to reduce the cost of breast cancer drugs.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	16826
answer	answer is ministerial correction date of answer 25/11/2015 answer text <p>Improving the availability and use of effective medicines for all cancers, including breast cancer, is a key priority. We continue to work with the pharmaceutical industry on a range of issues, including the pricing of medicines, through mechanisms such as the Pharmaceutical Price Regulation Scheme and the statutory scheme.</p><br /><p>The independent National Institute for Health and Care Excellence (NICE) provides evidence-based guidance on the clinical and cost effectiveness of drugs and other health technologies for the NHS in England.</p><br /><p>On 19 November 2015, NHS England and NICE launched a 12 week consultation on draft proposals on the future direction of the Cancer Drugs Fund. The consultation is open until 11 February 2016 and further information is available at:</p><br /><p><a href="http://www.engage.england.nhs.uk/consultation/cdf-consultation" target="_blank">www.engage.england.nhs.uk/consultation/cdf-consultation</a></p><br /><p>We take the issue of ensuring rapid access to innovative therapies very seriously. The independent Accelerated Access Review is looking at how we can speed up access for NHS patients to innovative and cost effective new medicines, diagnostics, medical technologies and digital products. The review published its interim report on 27 October 2015, and its full report and recommendations are expected in spring 2016.</p><br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/11/2015 14:45:25 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon